Publication digest
The Publication Digests section of this Learning Zone provides simplified detail and graphical summaries of the latest published research on chronic kidney disease treatments.
The peer-reviewed article in this section describes clinical evidence for the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of chronic kidney disease.
Dapagliflozin in patients with chronic kidney disease
The DAPA-CKD trial found that dapagliflozin is a safe and effective medication for the treatment of chronic kidney disease in patients with or without diabetes.
Canagliflozin in patients with type 2 diabetes and chronic kidney disease
The CREDENCE trial demonstrated canagliflozin was safe and effective for reducing the risk of adverse renal outcomes in patients with type 2 diabetes and chronic kidney disease.
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
The FIDELIO-DKD clinical trial explored ways to slow chronic kidney disease (CKD) progression and reduce cardiovascular morbidity and mortality in people with advanced CKD and type 2 diabetes.
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors AstraZeneca, who have reviewed the content only for scientific accuracy. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.